Literature DB >> 19010862

Relapse-free survival in breast cancer patients is associated with a gene expression signature characteristic for inflammatory breast cancer.

Steven Van Laere1, Tim Beissbarth, Ilse Van der Auwera, Gert Van den Eynden, Xuan Bich Trinh, Hilde Elst, Paul Van Hummelen, Peter van Dam, Eric Van Marck, Peter Vermeulen, Luc Dirix.   

Abstract

PURPOSE: We hypothesize that a gene expression profile characteristic for inflammatory breast cancer (IBC), an aggressive form of breast cancer associated with rapid cancer dissemination and poor survival, might be related to tumor aggressiveness in non-IBC (nIBC). EXPERIMENTAL
DESIGN: RNA from 17 IBC samples and 40 nIBC samples was hybridized onto Affymetrix chips. A gene signature predictive of IBC was identified and applied onto 1,157 nIBC samples with survival data of 881 nIBC samples. Samples were classified as IBC-like or nIBC-like. The IBC signature classification was compared with the classifications according to other prognostically relevant gene signatures and clinicopathologic variables. In addition, relapse-free survival (RFS) was compared by the Kaplan-Meyer method.
RESULTS: Classification according to the IBC signature is significantly (P < 0.05) associated with the cell-of-origin subtypes, the wound healing response, the invasive gene signature, the genomic grade index, the fibroblastic neoplasm signature, and the 70-gene prognostic signature. Significant associations (P < 0.01) were found between the IBC signature and tumor grade, estrogen receptor status, ErbB2 status, and patient age at diagnosis. Patients with an IBC-like phenotype show a significantly shorter RFS interval (P < 0.05). Oncomine analysis identified cell motility as an important concept linked with the IBC signature.
CONCLUSIONS: We show that nIBC carcinomas having an IBC-like phenotype have a reduced RFS interval. This suggests that IBC and nIBC show comparable phenotypic traits, for example augmented cell motility, with respect to aggressive tumor cell behavior. This observation lends credit to the use of IBC to study aggressive tumor cell behavior.

Entities:  

Mesh:

Year:  2008        PMID: 19010862     DOI: 10.1158/1078-0432.CCR-08-1077

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  11 in total

1.  Overexpression of COX-2 in celecoxib-resistant breast cancer cell lines.

Authors:  Balraj Singh; LaTashia R Irving; Karen Tai; Anthony Lucci
Journal:  J Surg Res       Date:  2010-05-26       Impact factor: 2.192

2.  Decreased expression of ABAT and STC2 hallmarks ER-positive inflammatory breast cancer and endocrine therapy resistance in advanced disease.

Authors:  Maurice P H M Jansen; Leen Sas; Anieta M Sieuwerts; Caroline Van Cauwenberghe; Diana Ramirez-Ardila; Maxime Look; Kirsten Ruigrok-Ritstier; Pascal Finetti; François Bertucci; Mieke M Timmermans; Carolien H M van Deurzen; John W M Martens; Iris Simon; Paul Roepman; Sabine C Linn; Peter van Dam; Marleen Kok; Filip Lardon; Peter B Vermeulen; John A Foekens; Luc Dirix; Els M J J Berns; Steven Van Laere
Journal:  Mol Oncol       Date:  2015-03-04       Impact factor: 6.603

3.  Inflammatory breast cancer: high risk of contralateral breast cancer compared to comparably staged non-inflammatory breast cancer.

Authors:  Catherine Schairer; Linda M Brown; Phuong L Mai
Journal:  Breast Cancer Res Treat       Date:  2011-03-09       Impact factor: 4.872

4.  Prognostic Significance of a Novel Score Model Based on Preoperative Indicators in Patients with Breast Cancer Spine Metastases (BCSM).

Authors:  Chenglong Zhao; Yao Wang; Xiaopan Cai; Wei Xu; Dongsheng Wang; Ting Wang; Qi Jia; Haiyi Gong; Haitao Sun; Zhipeng Wu; Jianru Xiao
Journal:  Cancer Manag Res       Date:  2020-11-10       Impact factor: 3.989

5.  Integrated miRNA and mRNA expression profiling of the inflammatory breast cancer subtype.

Authors:  I Van der Auwera; R Limame; P van Dam; P B Vermeulen; L Y Dirix; S J Van Laere
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

6.  A ranking-based meta-analysis reveals let-7 family as a meta-signature for grade classification in breast cancer.

Authors:  Yasemin Oztemur; Tufan Bekmez; Alp Aydos; Isik G Yulug; Betul Bozkurt; Bala Gur Dedeoglu
Journal:  PLoS One       Date:  2015-05-15       Impact factor: 3.240

7.  Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins.

Authors:  Jacob J Kennedy; Susan E Abbatiello; Kyunggon Kim; Ping Yan; Jeffrey R Whiteaker; Chenwei Lin; Jun Seok Kim; Yuzheng Zhang; Xianlong Wang; Richard G Ivey; Lei Zhao; Hophil Min; Youngju Lee; Myeong-Hee Yu; Eun Gyeong Yang; Cheolju Lee; Pei Wang; Henry Rodriguez; Youngsoo Kim; Steven A Carr; Amanda G Paulovich
Journal:  Nat Methods       Date:  2013-12-08       Impact factor: 28.547

8.  miRNome of inflammatory breast cancer.

Authors:  Diana V Maltseva; Vladimir V Galatenko; Timur R Samatov; Svetlana O Zhikrivetskaya; Nadezhda A Khaustova; Ilya N Nechaev; Maxim U Shkurnikov; Alexey E Lebedev; Irina A Mityakina; Andrey D Kaprin; Udo Schumacher; Alexander G Tonevitsky
Journal:  BMC Res Notes       Date:  2014-12-04

9.  Inflammatory breast carcinoma as a model of accelerated self-metastatic expansion by intravascular growth.

Authors:  P B Vermeulen; S J Van Laere; L Y Dirix
Journal:  Br J Cancer       Date:  2009-08-25       Impact factor: 7.640

10.  Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers.

Authors:  Hiroko Masuda; Keith A Baggerly; Ying Wang; Takayuki Iwamoto; Takae Brewer; Lajos Pusztai; Kazuharu Kai; Takahiro Kogawa; Pascal Finetti; Daniel Birnbaum; Luc Dirix; Wendy A Woodward; James M Reuben; Savitri Krishnamurthy; W Symmans; Steven J Van Laere; François Bertucci; Gabriel N Hortobagyi; Naoto T Ueno
Journal:  Breast Cancer Res       Date:  2013-11-25       Impact factor: 6.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.